GleamWall
中文EN

BHIC BioScience Health Innovations, Inc.

Services-Computer Processing & Data Preparation · OTC · SEC CIK 1784440 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.4%
TTM net income YoY-190.2%
TTM EPS YoY-187.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin54.4%
Operating margin-17.4%
Net margin-18.4%
FCF margin—
EBITDA margin—

Returns

ROE-34.5%
ROA-30.3%
ROIC (approx.)-66.0%
Asset turnover1.64x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.69x
Accruals ratio20.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$5.69M$1.84M
Cost of revenue$2.45M$536,078
Gross profit$3.24M$1.31M
R&D expense$161,353$25,908
SG&A expense$2.21M$1.15M
Operating income$719,051$87,000
Income tax$76,961$0
Net income$642,090$87,000
EPS (basic)0.060.01
EPS (diluted)0.060.01
Weighted avg. shares (diluted)11.40M10.90M
Balance sheet
Cash & equivalents$661,925$662,517
Receivables$399,257$100,285
Inventory$336,348$58,319
Current assets$1.56M$847,751
Intangibles$82,887$26,037
Total assets$1.71M$873,788
Total liabilities$229,851$38,548
Shareholders' equity$1.48M$835,240
Shares outstanding10.98M10.98M
Cash flow statement
Operating cash flow$172,178$23,188
Investing cash flow-$56,850-$26,037
Financing cash flow-$115,920$646,128

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.